CinnaGen
Haleh Hamedifar has extensive experience in the pharmaceutical industry, currently serving as Chairperson at CinnaGen since February 2023. As the General Manager and Founder of CinnaGen Group since February 2015, and as CEO and board member of CinnaGen Co. since 1998, Haleh has significantly contributed to the field. Previous experience includes a role as Production Manager at Exir Pharmaceutical Co. in 1997. Haleh Hamedifar holds a Doctor of Pharmacy (Pharm.D.) degree from Tehran University of Medical Sciences, obtained between 1990 and 1995.
This person is not in any teams
This person is not in any offices
CinnaGen
CinnaGen Co. has founded in 1994 with the goal of manufacturing High-Tech products in biotechnology and related fields. Since its start of operations with 4 scientists, CinnaGen has grown to become the biggest Biopharma manufacturer and biotech exporter in the region. The concept was to be active in the research and development of new potent biotech-based products for covering regional market. Enzymes, molecular biology reagents and PCR kits are the first products and then CinnaGen use its proprietary set of technologies to endow Monoclonal Antibodies for blood group typing. The next important step for CinnaGen was the entry to the therapeutic recombinant protein area. Today the company prides itself in its innovative skills meeting today’s challenges. We focus our efforts on developing the biogenerics candidates in the areas of immunological diseases and oncology as well as providing contract research development services. The company is spending over 20 percent of its total turnover on R&D activities. CinnaGen is strategically positioned to become and remain leading biotechnology company in the region. Our aim is to use our expertise to identify and acquire selected products, through strategic partnerships to promote sustainable development in human health.